Kymera Therapeutics

KYMRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.940 B

$107.52 +1.04%

Close of 7 Aug 2026

Revenue

$39.2M

#2818 by revenue

Earnings

$311.4M

#822 by earnings

Shares outstanding

83,150,618

Latest filing cover page

P/E ratio

28.7

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#13Krystal BiotechKRYS$9.66B
#14RepligenRGEN$9.25B
#15Kymera TherapeuticsKYMR$8.94B
#16QiagenQGEN$8.72B
#17VaxcytePCVX$8.64B

Where these numbers come from

Share counts and financials for Kymera Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.